Women's constructions of the 'right time' to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy

BMC Women's Health

Volumn 10, Issue , 2010, Pages

  Howard, A Fuchsia ^a   Bottorff, Joan L ^b   Balneaves, Lynda G ^a   Kim Sing, Charmaine ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; COMPARATIVE STUDY; DECISION MAKING; EMOTION; FEMALE; HEALTH CARE SYSTEM; HETEROZYGOTE; HUMAN; MASTECTOMY; OVARIECTOMY; QUALITATIVE ANALYSIS; RISK REDUCTION; ADULT; AGED; BODY IMAGE; BREAST TUMOR; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MIDDLE AGED; OVARY TUMOR; PSYCHOLOGICAL ASPECT; TIME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BODY IMAGE; BREAST NEOPLASMS; DECISION MAKING; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MASTECTOMY; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; RISK REDUCTION BEHAVIOR; TIME FACTORS;

EID: 77955184696     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-10-24     Document Type: Article

References (55)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennet LM, Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71. 10.1126/science.7545954, 7545954.
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792. 10.1038/378789a0, 8524414.
3. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J of Hum Genet 2003, 72:1117-1130.
4. Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008, 8:155. 10.1186/1471-2407-8-155, 2447846, 18513387.
5. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir S, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 1998, 62:676-689. 10.1086/301749, 1376944, 9497246.
6. Antill Y, Reynolds J, Young MA, Kirk J, Tucker K, Bogtstra T, Wong S, Dudding T, Di Iulio J, Phillips KA. Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. Eur J Cancer 2006, 42:621-628. 10.1016/j.ejca.2005.11.020, 16434187.
7. Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White MA, Artioli G, Dudlicek L, Olopade OI. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med 2008, 10:161-166. 10.1097/GIM.0b013e318163487d, 18344704.
8. Evans DG, Lalloo F, Ashcroft L, Shenton A, Clancy T, Baildam AD, Brain A, Hopwood P, Howell A. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev 2009, 18:2318-2324. 10.1158/1055-9965.EPI-09-0171, 19661091.
9. Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer 2007, 7:875-882. 10.3816/CBC.2007.n.053, 18269778.
10. Josephson U, Wickman M, Sandelin K. Initial experiences of women from hereditary breast cancer families after bilateral prophylactic mastectomy: A retrospective study. Eur J Surg Oncol 2000, 26:351-356. 10.1053/ejso.1999.0897, 10873354.
11. Lloyd SM, Watson M, Oaker G, Sacks N, Querci della Rovere U, Gui G. Understanding the experience of prophylactic bilateral mastectomy: A qualitative study of ten women. Psychooncology 2000, 9:473-485. 10.1002/1099-1611(200011/12)9:6<473::AID-PON490>3.0.CO;2-T, 11180582.
12. Metcalfe KA, Esplen MJ, Goel V, Narod SA. Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. Psychooncology 2004, 13:14-25. 10.1002/pon.726, 14745742.
13. Horsman D, Wilson BJ, Avard D, Meschino WS, Kim-Sing C, Plante M, Eisen A, Howley HE, Simard J, . National Hereditary Cancer Task Force Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can 2007, 29:45-60. National Hereditary Cancer Task Force.
14. Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Moller P, Weitzel J, Sun P, Narod SA, . Hereditary Breast Cancer Clinical Study Group Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation. J Clinic Oncol 2008, 26:1093-1097. Hereditary Breast Cancer Clinical Study Group.
15. Brain K, Gravell C, France E, Fiander A, Gray J. An exploratory qualitative study of women's perceptions of risk management options for familial ovarian cancer: Implications for informed decision making. Gynecol Oncol 2004, 92:905-913. 10.1016/j.ygyno.2003.12.019, 14984959.
16. Hallowell N, Jacobs I, Richards M, Mackay J, Gore M. Surveillance or surgery? A description of the factors that influence high risk premenopausal women's decisions about prophylactic oophorectomy. J Med Genet 2001, 38:683-691. 10.1136/jmg.38.10.683, 1734749, 11594337.
17. Hamilton R, Williams JK, Bowers BJ, Calzone K. Life trajectories, genetic testing, and risk reduction decisions in 18-39 year old women at risk for hereditary breast and ovarian cancer. J Genet Couns 2009, 18:147-159. 10.1007/s10897-008-9200-1, 2834272, 18979190.
18. Howard AF, Balneaves LG, Bottorff JL. Women's decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: A systematic review. J Genet Couns 2009, 18:578-597. 10.1007/s10897-009-9245-9, 19802692.
19. Arver B, Haegermark A, Platten U, Lindblom A, Brandberg Y. Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian and colon cancer pre-disposing genes: A 12-month follow-up. Fam Cancer 2004, 3:109-116. 10.1023/B:FAME.0000039863.89137.f9, 15340261.
20. Hamilton JG, Lobel M, Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: A meta-analytic review. Health Psychol 2009, 28:510-518. 10.1037/a0014778, 2807362, 19594276.
21. Smith AW, Dougall AL, Posluszny DM, Somers TJ, Rubinstein WS, Baum A. Psychological distress and quality of life associated with genetic testing for breast cancer risk. Psychooncology 2008, 17:767-773. 10.1002/pon.1291, 17992698.
22. van Oostrom I, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, van Gool AR, Seynaeve C, van der Meer CA, Klijn JG, van Geel BN, Burger CW, Wladimiroff JW, Tibben A. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: A 5-year follow-up study. J Clin Oncol 2003, 21:3867-3874. 10.1200/JCO.2003.10.100, 14551306.
23. Butow PN, Lobb EA, Meiser B, Barratt A, Tucker KM. Psychological outcomes and risk perception after genetic testing and counselling in breast cancer: A systematic review. Med J Aust 2003, 178:77-81.
24. Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening: Psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology 2001, 10:231-241. 10.1002/pon.512.abs, 11351375.
25. Hurley KE, Miller SM, Costalas JW, Gillespie D, Daly MB. Anxiety/uncertainty reduction as a motivation for interest in prophylactic oophorectomy in women with a family history of ovarian cancer. J Womens Health Gend Based Med 2001, 10:189-199. 10.1089/152460901300039566, 11268302.
26. Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Seynaeve C, van Geel AN, Tilanus MM, Bartels CC, Verhoog LC, Brekelmans CT, Burger CW, Niermeijer MF. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: Emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 2002, 73:97-112. 10.1023/A:1015269620265, 12088120.
27. Meiser B, Butow P, Barratt A, Friedlander M, Gattas M, Kirk J, Suthers G, Walpole I, Tucker K. Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol 1999, 75:122-129. 10.1006/gyno.1999.5544, 10502438.
28. Meiser B, Butow P, Friedlander M, Schnieden V, Gattas M, Krik J, Suthers G, Haan E, Tucker K. Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J Clin Oncol 2000, 18:2250-2257.
29. Stefanek M, Enger C, Benkendorf J, Flamm Honig S, Lerman C. Bilateral prophylactic mastectomy decision making: A vignette study. Prevent Med 1999, 29:216-221.
30. Unic I, Verhoef LC, Stalmeier PF, Van Daal WAJ. Prophylactic mastectomy or screening in women suspected to have the BRCA1/2 mutation: A prospective pilot study of women's treatment choices and medical and decision-analytic recommendations. Med Decis Making 2000, 20:251-262. 10.1177/0272989X0002000301, 10929847.
31. McCullum M, Bottorff JL, Kelly M, Kieffer SA, Balneaves LG. Time to decide about risk-reducing mastectomy: A case series of BRCA1/2 gene mutation carriers. BMC Womens Health 2007, 7. 10.1186/1472-6874-7-3, 1829393, 17341306.
32. Howard AF, Balneaves LG, Bottorff JL, Rodney P. Preserving the self: the process of decision making about hereditary breast and ovarian cancer risk reduction. Qual Health Res
33. Babb SA, Swisher EM, Heller HN, Whelan AJ, Mutch DG, Herzog TJ, Rader JS. Qualitative evaluation of medical information processing needs of 60 women choosing ovarian cancer surveillance or prophylactic oophorectomy. J Genet Counsel 2002, 11:81-96.
34. Charmaz K. Constructing grounded theory: A practical guide through qualitative analysis 2006, Sage: California.
35. Strauss A, Corbin J. Basics of qualitative research: Techniques and procedures for developing grounded theory 1998, Sage: California.
36. Sandelowski M. Whatever happened to qualitative description?. Res Nurs Health 2000, 23:334-340. 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G, 10940958.
37. Morse JM, Field PA. Qualitative research methods for health professionals 1995, Sage: California, 2.
38. Narod S. New developments in breast cancer. Presentation at the 11th international meeting on the psychosocial aspects of genetic testing for hereditary cancer, Toronto, Ontario, 23-24 April 2009
39. d'Agincourt-Canning L. Genetic testing for hereditary breast and ovarian cancer: Responsibility and choice. Qual Health Res 2006, 16:97-118. 10.1177/1049732305284002, 16317179.
40. Matloff ET, Barnett RE, Bober SL. Unraveling the next chapter: Sexual development, body image, and sexual functioning in female BRCA carriers. Cancer J 2009, 15:15-18. 10.1097/PPO.0b013e31819585f1, 19197168.
41. Ray JA, Loescher LJ, Brewer M. Risk-reduction surgery decisions in high-risk women seen for genetic counseling. J Genet Couns 2005, 14:473-484. 10.1007/s10897-005-5833-5, 16388328.
42. Proulx M, Beaulieu MD, Loignon C, Mayrand MH, Maugard C, Bellavance N, Provencher D. Experiences and decisions that motivate women at increased risk of breast cancer to participate in an experimental screening program. J Genet Couns 2009, 18:160-172. 10.1007/s10897-008-9202-z, 19219540.
43. Hallowell N. A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy. Psychooncology 2000, 9:486-495. 10.1002/1099-1611(200011/12)9:6<486::AID-PON478>3.3.CO;2-P, 11180583.
44. Kenen R, Ardern-Jones A, Eeles R. "Social separation" among women under 40 years of age diagnosed with breast cancer and carrying a BRCA1 or BRCA2 mutation. J Genet Couns 2006, 15:149-162. 10.1007/s10897-005-9015-2, 16724273.
45. O'Connor AM, Jacobsen MJ. Decisional conflict: Supporting people experiencing uncertainty about options affecting their health 2007, http://decisionalaid.ohri.ca
46. Tan MB, Bleiker EM, Menke-Pluymers MB, Van Gool AR, van Dooren S, Van Geel BN, Tilanus-Linthorst MM, Bartels KC, Klijn JG, Brekelmans CT, Seynaeve C. Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy. Hered Cancer Clin Practice 2009, 7:6-8.
47. Metcalfe KA, Liede A, Hoodfar E, Scott A, Foulkes WD, Narod SA. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. J Med Genet 2000, 37:866-874. 10.1136/jmg.37.11.866, 1734476, 11073541.
48. Douglas HA, Hamilton RJ, Grubs RE. The effect of BRCA gene testing on family relationships: A thematic analysis of qualitative interviews. J Genet Couns 2009, 18:418-435. 10.1007/s10897-009-9232-1, 19479365.
49. Lim J, Macluran M, Price M, Bennett B, Butow P, . kConFab Psychosocial Group Short- and long-term impact of receiving genetic mutation results in women at increased risk for hereditary breast cancer. J Genet Couns 2004, 13:115-133. 10.1023/B:JOGC.0000018822.56297.a6, 15612172, kConFab Psychosocial Group.
50. Kenen R, Arden-Jones A, Eeles R. Healthy women from suspected hereditary breast and ovarian cancer families: The significant others in their lives. Eur J Cancer Care 2004, 13:169-179.
51. Kenen R, Arden-Jones A, Eeles R. We are talking, but are they listening? communication patterns in families with a history of breast/ovarian cancer (HBOC). Psychooncology 2004, 13:335-345. 10.1002/pon.745, 15133774.
52. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA, . Hereditary Breast Cancer Clinical Study Group International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008, 122:2017-2022. 10.1002/ijc.23340, 18196574, Hereditary Breast Cancer Clinical Study Group.
53. Julian-Reynier CM, Bouchard LJ, Evans DG, Eisinger FA, Foulkes WD, Kerr B, Blancquaert IR, Moatti JP, Sobol HH. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: Differences among English, French, and Canadian women. Cancer 2001, 92:959-968. 10.1002/1097-0142(20010815)92:4<959::AID-CNCR1406>3.0.CO;2-V, 11550171.
54. Health Council of Canada Rethinking reform: Health care renewal in Canada, 2003 - 2008. Health Council 2008, Health Council of Canada., http://http//www.healthcouncilcanada.ca
55. British Columbia Women's Hospital and Health Centre and British Columbia Centre or Excellence for Women's Health Advancing the health of girls and women: A women's health strategy for British Columbia. 2004 British Columbia Women's Hospital and Health Centre and British Columbia Centre or Excellence for Women's Health., http://www.bccewh.bc.ca